IP Library Granted Patent US 12697414
Granted Patent B2
US 12697414 · App. 18/614,296 · Granted Aug 4, 2026

Adipose compositions and methods of use thereof

Inventor: Alla Danilkovitch (Columbia, MD)
Assignee: BRITECYTE INC.
A61L27/3691
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12697414
App. No.
18/614,296
Granted
Aug 4, 2026
Kind
B2
Abstract

Disclosed are devitalized adipose tissue. Disclosed are compositions comprising devitalized adipose tissue. In some aspects, the compositions further comprise a cryopreservation or lyophilization solution. Disclosed are cryopreserved or lyophilized devitalized adipose tissue. Disclosed are methods of augmenting a soft tissue site of a subject in need thereof comprising administering to the subject a composition comprising devitalized adipose tissue. Disclosed are methods of treating a subject having fat pad atrophy comprising administering to the subject a composition comprising devitalized adipose tissue. Disclosed are methods of treating a subject having lipodystrophy comprising administering to the subject a composition comprising devitalized adipose tissue. Disclosed are methods of treating a subject having a metabolic disease or condition comprising administering to the subject a composition comprising devitalized adipose tissue.

Claims (18)

1 . A cryopreserved composition comprising autologous or allogeneic devitalized adipose tissue,

wherein the devitalized adipose tissue comprises at least 50% of native lipids,

wherein the devitalized adipose tissue comprises at least 70% of native growth factors,

wherein the devitalized adipose tissue is not decellularized,

wherein the devitalized adipose tissue retains its native structure,

wherein the composition does not comprise free lipids,

wherein the composition does not comprise TNFα, and

wherein the devitalized adipose tissue comprises less than 5% native viable cells.

2 . The composition of claim 1 , wherein the devitalized adipose tissue is minced.

3 . The composition of claim 2 , wherein the minced devitalized adipose tissue comprises pieces of adipose tissue less than 1 mm in size.

4 . The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.

5 . The composition of claim 1 , further comprising one or more lyopreservative agents.

6 . The composition of claim 5 , wherein the one or more lyopreservative agents is a sugar.

7 . The composition of claim 6 , wherein the sugar is trehalose.

8 . The composition of claim 5 , wherein the one or more lyopreservative agents is human serum albumin.

9 . The composition of claim 1 , wherein the devitalized adipose tissue comprises less than 5%, 2%, 1%, 0.5%, 0.2%, 0.1%, 0.05% or 0.01% peroxidized lipids of total lipids.

10 . The composition of claim 1 , wherein the growth factors are angiogenic growth factors, vascular endothelial growth factors, insulin like growth factors, hepatocyte growth factor, platelet-derived growth factor, or fibroblast growth factors.

11 . The composition of claim 1 , wherein the devitalized adipose tissue is non-radiated.